Lexicon Pharmaceuticals, Inc. (LXRX)
- Previous Close
0.7200 - Open
0.7200 - Bid 0.5693 x 100
- Ask 0.7625 x 100
- Day's Range
0.6525 - 0.7200 - 52 Week Range
0.2800 - 2.4500 - Volume
4,737,235 - Avg. Volume
15,819,451 - Market Cap (intraday)
261.488M - Beta (5Y Monthly) 1.08
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5700 - Earnings Date May 13, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.60
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its orally-delivered small molecule drug candidates under development include sotagliflozin for the treatment of hypertrophic cardiomyopathy or HCM and type 1 diabetes that is in Phase 3 clinical trial; LX9211, which has completed Phase II clinical trials for the treatment of neuropathic pain; and LX9851 for the treatment of obesity and associated cardiometabolic disorders, as well as for weight management. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
www.lexpharma.comRecent News: LXRX
View More
Performance Overview: LXRX
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LXRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LXRX
View MoreValuation Measures
Market Cap
261.49M
Enterprise Value
131.93M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.41
Price/Book (mrq)
1.79
Enterprise Value/Revenue
4.24
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-43.77%
Return on Equity (ttm)
-167.66%
Revenue (ttm)
31.08M
Net Income Avi to Common (ttm)
-200.4M
Diluted EPS (ttm)
-0.5700
Balance Sheet and Cash Flow
Total Cash (mrq)
237.96M
Total Debt/Equity (mrq)
72.68%
Levered Free Cash Flow (ttm)
-98.3M
Research Analysis: LXRX
View MoreResearch Reports: LXRX
View MoreDaily – Vickers Top Buyers & Sellers for 10/13/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Insider Picks for 09/20/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 09/19/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 09/18/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.